United Therapeutics Corp. unveiled unexpectedly positive Phase III data for its nebulized treprostinil product, Tyvaso, in idiopathic pulmonary fibrosis (IPF), a notoriously difficult-to-treat lung disease. The inhaled drug achieved its primary endpoint, improving forced vital capacity at 52 weeks by 95.6 mL and demonstrating consistent benefits across patient subgroups, including those on existing approved IPF therapies. Safety and tolerability profiles were consistent with earlier studies. The findings support a supplemental New Drug Application (sNDA) filing with the FDA anticipated next year. Analysts predict the approval could open a market exceeding $4 billion. Tyvaso’s shares surged on the news, signaling strong investor enthusiasm. The data represent a significant stride in IPF treatment, expanding therapeutic options for patients with limited choices.